Command Palette

Search for a command to run...

Clinical Trials · NCT06267092

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
164
Start date
Feb 2024
Locations
1 site, Germany
Primary endpoint
Change in mean postprandial appetite score based on visual analogue scale (VAS)
View Semaglutide compound reference